Erratum: Author Corrections to “Canadian Cardiovascular Society 2023 Guidelines on the Fitness to Drive” [Can J Cardiol 40 (2024):500-523, (S0828282X23017555), (10.1016/j.cjca.2023.09.033)]

In the article, “Canadian Cardiovascular Society 2023 Guidelines on the Fitness to Drive” [Can J Cardiol 40 (2024):500-23], some errors were found in the text following publication in the April 2024 issue. 1. In Table 2: a. Page 506, in the Valvular Heart Disease Treated With Transcatheter Therapy section, under the Commercial Driving column, in the Aortic Stenosis (Treated With TAVR) row, the final bullet incorrectly states: • LVEF > 30%However, it should have read: • LVEF ≥ 30%b. On page 507, in the Surgically Treated Valve Disease section, under the Commercial Driving column, in the Aortic Stenosis (Treated With SAVR) row, the final bullet incorrectly states: • LVEF > 30%However, it should have read: • LVEF ≥ 30% 2. In Table 3, on page 509, the abbreviation EF (for ejection fraction) was incorrectly used 3 times in the Commercial Driving column, when the abbreviation for LVEF (for left ventricular ejection fraction) should have been used in these places.3. On page 509, in the final paragraph in the left column, the second and third sentences read as follows:For those patients with an EF ≤ 30% there is a 10% annual risk of death and a 5% annual risk of SCD. Commercial driving therefore is not recommended for patients with an EF < 30%, even if they are asymptomatic, because the acceptable SCI annual risk for commercial drivers has been set at 1%. However, these should have read as follows (corrections are in bold): For those patients with an LVEF < 30% there is a 10% annual risk of death and a 5% annual risk of SCD. Commercial driving therefore is not recommended for patients with an LVEF < 30%, even if they are asymptomatic, because the acceptable SCI annual risk for commercial drivers has been set at 1%. These errors have been corrected in the online version of the article.